Immunoadjuvant therapy is a novel pharmacological intervention for improving the outcomes of conversion therapy in advanced digestive tract tumors. How to transform a "cold" tumor into a "hot" tumor synchronously during surgical exploration represents a viable approach to enhancing the immunotherapy response rate. Mitochondria play an important role in cancer diseases, as the release of mitochondrial-specific molecules, including mitochondrial (mt) DNA, leads to the initiation and/or amplification of pro-inflammatory responses in host cells. Furthermore, mtDNA might be an inducer to trigger immune responses, such as activating the Cyclic GMP-AMP Synthase (cGAS)-STING pathway-related natural immune response, pyroptosis, ICD, etc.
In pursuit of a more in-depth understanding of these topics, our Research Topic focuses on mitochondrial damage and the underlying mechanisms, including molecules related to inflammasomes, the roles of mitochondrial damage in immunity, and cross-talk between the different death pathways. We will explore how mitochondrial damage interacts with the immune system and tumor microenvironment, with an emphasis on developing precise pyroptotic treatments and novel cancer immunotherapies.
Our topic encourages submissions of original research and review articles. Relevant subtopics include, but are not limited to:
1. Molecular mechanisms and signaling pathways underlying mitochondrial damage in inflammatory diseases, tumor progression, and immunotherapy.
2. Therapeutic strategies for mitochondrial damage and clinical applications of immunotherapy drugs (including nanomedicines) related to mitochondrial damage.
3. Integrated treatment that involves immune modulation via mitochondrial damage.
4. Exploration and development of biomarkers and indicators for monitoring mitochondrial damage.
5. Preclinical models and translational research related to mitochondrial damage.
6. Novel pharmaceutical strategies targeting mitochondria, such as nanoparticle-based modalities.
7. Clinical trials of novel pharmaceuticals related to immunomodulation via mitochondrial damage.
Please NOTE: To uphold the focus of this Research Topic, manuscripts that solely consist of bioinformatics or computational analyses without being validated through independent cohorts or in vitro/in vivo investigations, are not within the scope of this Research Topic and will not be accepted.
Immunoadjuvant therapy is a novel pharmacological intervention for improving the outcomes of conversion therapy in advanced digestive tract tumors. How to transform a "cold" tumor into a "hot" tumor synchronously during surgical exploration represents a viable approach to enhancing the immunotherapy response rate. Mitochondria play an important role in cancer diseases, as the release of mitochondrial-specific molecules, including mitochondrial (mt) DNA, leads to the initiation and/or amplification of pro-inflammatory responses in host cells. Furthermore, mtDNA might be an inducer to trigger immune responses, such as activating the Cyclic GMP-AMP Synthase (cGAS)-STING pathway-related natural immune response, pyroptosis, ICD, etc.
In pursuit of a more in-depth understanding of these topics, our Research Topic focuses on mitochondrial damage and the underlying mechanisms, including molecules related to inflammasomes, the roles of mitochondrial damage in immunity, and cross-talk between the different death pathways. We will explore how mitochondrial damage interacts with the immune system and tumor microenvironment, with an emphasis on developing precise pyroptotic treatments and novel cancer immunotherapies.
Our topic encourages submissions of original research and review articles. Relevant subtopics include, but are not limited to:
1. Molecular mechanisms and signaling pathways underlying mitochondrial damage in inflammatory diseases, tumor progression, and immunotherapy.
2. Therapeutic strategies for mitochondrial damage and clinical applications of immunotherapy drugs (including nanomedicines) related to mitochondrial damage.
3. Integrated treatment that involves immune modulation via mitochondrial damage.
4. Exploration and development of biomarkers and indicators for monitoring mitochondrial damage.
5. Preclinical models and translational research related to mitochondrial damage.
6. Novel pharmaceutical strategies targeting mitochondria, such as nanoparticle-based modalities.
7. Clinical trials of novel pharmaceuticals related to immunomodulation via mitochondrial damage.
Please NOTE: To uphold the focus of this Research Topic, manuscripts that solely consist of bioinformatics or computational analyses without being validated through independent cohorts or in vitro/in vivo investigations, are not within the scope of this Research Topic and will not be accepted.